« Back to Record
Citation APA

Sulkowski, M., Matthews, G., Molina, J.-M., Moreno, C., Pineda, J. A., Pulido, F., Rivero, A., Rockstroh, J., Hernandez, D., McPhee, F., Eley, T., Fessel, W. J., Liu, Z., Mendez, P., Hughes, E., Noviello, S., Ackerman, P., Lazzarin, A., Berenguer, J., Zakharova, N., Cheinquer, H., Côté, P., Dieterich, D., & Gadano, A. (2017). Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Hepatology International, 11(2), 188-198. doi:10.1007/s12072-017-9788-z


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/249632

Sulkowski, M., Matthews, G., Molina, J.-M., Moreno, C., Pineda, J. A., Pulido, F., Rivero, A., Rockstroh, J., Hernandez, D., McPhee, F., Eley, T., Fessel, W. J., Liu, Z., Mendez, P., Hughes, E., Noviello, S., Ackerman, P., Lazzarin, A., Berenguer, J., Zakharova, N., Cheinquer, H., Côté, P., Dieterich, D., & Gadano, A. (2017). Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Hepatology International, 11(2), 188-198. doi:10.1007/s12072-017-9788-z